Cargando…

Treatment options for advanced gastric cancer with peritoneal metastasis: experience from a single institution in Korea

PURPOSE: This study aimed to compare treatment options and outcomes based on peritoneal cancer index (PCI) among patients with peritoneal metastasis (PM) of advanced gastric cancer (AGC). METHODS: Between January 2016 and July 2019, clinicopathological data of patients with AGC diagnosed with PM wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dong-Wook, Youn, Sang Il, Jee, Ye Seob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Surgical Society 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019985/
https://www.ncbi.nlm.nih.gov/pubmed/33854990
http://dx.doi.org/10.4174/astr.2021.100.4.209
_version_ 1783674492713697280
author Kim, Dong-Wook
Youn, Sang Il
Jee, Ye Seob
author_facet Kim, Dong-Wook
Youn, Sang Il
Jee, Ye Seob
author_sort Kim, Dong-Wook
collection PubMed
description PURPOSE: This study aimed to compare treatment options and outcomes based on peritoneal cancer index (PCI) among patients with peritoneal metastasis (PM) of advanced gastric cancer (AGC). METHODS: Between January 2016 and July 2019, clinicopathological data of patients with AGC diagnosed with PM were reviewed. Different treatment methods were performed according to the PCI score: (1) group A (PCI ≤ 13) received cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with postoperative intraperitoneal (IP) and systemic chemotherapy (n = 29), while (2) group B (PCI > 13) received IP chemotherapy with systemic chemotherapy (n = 22). RESULTS: Clinical outcomes of 51 patients at the Dankook University Hospital were reviewed. Group A had a significantly lower mean PCI score (9.8 ± 6.9 vs. 32.6 ± 7.1, P < 0.01) than group B, with 25 patients (86.2%) achieving complete cytoreduction. Complications occurred in 16 patients (31.4%), none of who suffered mortality (group A: 11 patients, 37.9% vs. group B: 5 patients, 22.7%; P = 0.25). Among the morbidity, 5 cases (17.2%) and 2 cases (9.1%) exhibited a Clavien-Dindo grade greater than III in groups A and B, respectively (P = 0.04). Groups A and B had an overall median survival time of 34.0 and 16.0 months, respectively (P = 0.03). CONCLUSION: Patients with PM of AGC received different treatments according to their PCI score. When accompanied with careful patient selection, our approach may be considered an acceptable option for the treatment of PM of AGC.
format Online
Article
Text
id pubmed-8019985
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Korean Surgical Society
record_format MEDLINE/PubMed
spelling pubmed-80199852021-04-13 Treatment options for advanced gastric cancer with peritoneal metastasis: experience from a single institution in Korea Kim, Dong-Wook Youn, Sang Il Jee, Ye Seob Ann Surg Treat Res Original Article PURPOSE: This study aimed to compare treatment options and outcomes based on peritoneal cancer index (PCI) among patients with peritoneal metastasis (PM) of advanced gastric cancer (AGC). METHODS: Between January 2016 and July 2019, clinicopathological data of patients with AGC diagnosed with PM were reviewed. Different treatment methods were performed according to the PCI score: (1) group A (PCI ≤ 13) received cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with postoperative intraperitoneal (IP) and systemic chemotherapy (n = 29), while (2) group B (PCI > 13) received IP chemotherapy with systemic chemotherapy (n = 22). RESULTS: Clinical outcomes of 51 patients at the Dankook University Hospital were reviewed. Group A had a significantly lower mean PCI score (9.8 ± 6.9 vs. 32.6 ± 7.1, P < 0.01) than group B, with 25 patients (86.2%) achieving complete cytoreduction. Complications occurred in 16 patients (31.4%), none of who suffered mortality (group A: 11 patients, 37.9% vs. group B: 5 patients, 22.7%; P = 0.25). Among the morbidity, 5 cases (17.2%) and 2 cases (9.1%) exhibited a Clavien-Dindo grade greater than III in groups A and B, respectively (P = 0.04). Groups A and B had an overall median survival time of 34.0 and 16.0 months, respectively (P = 0.03). CONCLUSION: Patients with PM of AGC received different treatments according to their PCI score. When accompanied with careful patient selection, our approach may be considered an acceptable option for the treatment of PM of AGC. The Korean Surgical Society 2021-04 2021-03-30 /pmc/articles/PMC8019985/ /pubmed/33854990 http://dx.doi.org/10.4174/astr.2021.100.4.209 Text en Copyright © 2021, the Korean Surgical Society http://creativecommons.org/licenses/by-nc/4.0/ Annals of Surgical Treatment and Research is an Open Access Journal. All articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Dong-Wook
Youn, Sang Il
Jee, Ye Seob
Treatment options for advanced gastric cancer with peritoneal metastasis: experience from a single institution in Korea
title Treatment options for advanced gastric cancer with peritoneal metastasis: experience from a single institution in Korea
title_full Treatment options for advanced gastric cancer with peritoneal metastasis: experience from a single institution in Korea
title_fullStr Treatment options for advanced gastric cancer with peritoneal metastasis: experience from a single institution in Korea
title_full_unstemmed Treatment options for advanced gastric cancer with peritoneal metastasis: experience from a single institution in Korea
title_short Treatment options for advanced gastric cancer with peritoneal metastasis: experience from a single institution in Korea
title_sort treatment options for advanced gastric cancer with peritoneal metastasis: experience from a single institution in korea
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019985/
https://www.ncbi.nlm.nih.gov/pubmed/33854990
http://dx.doi.org/10.4174/astr.2021.100.4.209
work_keys_str_mv AT kimdongwook treatmentoptionsforadvancedgastriccancerwithperitonealmetastasisexperiencefromasingleinstitutioninkorea
AT younsangil treatmentoptionsforadvancedgastriccancerwithperitonealmetastasisexperiencefromasingleinstitutioninkorea
AT jeeyeseob treatmentoptionsforadvancedgastriccancerwithperitonealmetastasisexperiencefromasingleinstitutioninkorea